About us

Odimma is a French biotech company with a unique approach in active personalized cancer immunotherapy. Odimma believes in the future of precision medicine, and leverages recent advances in the field of immuno-oncology to fight the most hard-to-treat cancers.


Therapeutic Vaccines, Neoantigens, Personalized Immunotherapy

Business offer

By harnessing the ability of the patient’s own immune system to specifically recognize non-self-targets displayed by the tumor, also called neoantigens, Odimma has designed a potent next-generation personalized immunization platform.

Field of application
  • therapeutic vaccines
Therapeutic application
  • oncology


  • Target Selection & Validation
  • Research exploratory companion biomarkers
  • Immunotherapy Lead Generation
  • Pharmacology & Biological activity
  • Mode of Action
  • Therapeutic efficacy
  • Cell activation
  • In-vivo activation (in human transgenic mouse models)
  • Immunotherapy Lead Optimization
  • Proof of concept
  • in-vitro & ex-vivo models
  • in-vivo models
  • Preclinical biomarkers
  • Mechanism/Function
  • Mechanism of action
  • Research exploratory Companion biomarkers
  • Human biomarkers
  • Predictive biomarkers
  • Treatment efficacy
  • Population stratification
  • Risk/benefit profile
  • Disease progression / follow-up
  • Formulation
  • Formulation
  • Dose
  • Adjuvants
  • Delivery
  • Route of Administration
  • Devices associated
  • Clinical Trials
  • Phase I


  • Therapeutic product